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Summary
Myelofibrosis (MF) patients can present with a wide spectrum of disease
characteristics. We analysed the consistency of ruxolitinib efficacy across
patient subgroups in the COntrolled MyeloFibrosis Study With ORal JAK
Inhibitor Treatment (COMFORT-I,) a double-blind trial, where patients
with intermediate-2 or high-risk MF were randomized to twice-daily oral
ruxolitinib (n = 155) or placebo (n = 154). Subgroups analysed included
MF subtype (primary, post-polycythaemia vera, post-essential thrombocy-
thaemia), age ( 65, > 65 years), International Prognostic Scoring System
risk group, baseline Eastern Cooperative Oncology Group performance sta-
tus (0, 1,  2), JAK2 V617F mutation (positive, negative), baseline haemo-
globin level ( 100, <100 g/l), baseline platelet count (100–200 9 109/l,
>200 9 109/l), baseline palpable spleen size ( 10, >10 cm), and baseline
quartile of spleen volume and Total Symptom Score (TSS; Q1 = lowest,
Q4 = highest). Mean percentage change from baseline to week 24 in spleen
volume and TSS were calculated for ruxolitinib and placebo in each sub-
group. Overall survival was estimated by Kaplan–Meier method according
to original randomization group. In ruxolitinib-treated patients, reductions
in spleen volume and TSS and evidence of improved survival relative to
placebo across subgroups were consistent with those seen in the COM-
FORT-I population, confirming that ruxolitinib is an effective therapy for
the spectrum of MF patients studied in COMFORT-I.
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Myelofibrosis (MF) is a rare and life-threatening myeloprolif-
erative neoplasm that can arise de novo [primary MF
(PMF)] or evolve from polycythaemia vera (PV), i.e. post-
polycythaemia vera MF (PPV-MF), or essential thrombocy-
thaemia (ET), i.e. post-ET MF (PET-MF) (Barosi et al, 2008;
Vardiman et al, 2009; Tefferi, 2011). Dysregulated Janus
kinase/signal transducers and activators of transcription
(JAK-STAT) signalling, resulting from gain- or loss-of-func-
tion mutations and/or high circulating levels of inflammatory
cytokines, plays a key role in the pathogenesis of MF (Vain-
chenker et al, 2011). The JAK2 V617F mutation is present in
approximately 50–60% of patients with PMF or ET and in
over 95% of patients with PV (Nguyen & Gotlib, 2012). Dys-
regulation of the JAK-STAT signalling pathway in MF is
additionally related to mutations in genes such as JAK2 exon
12, MPL exon 10, SH2B3, members of the Casitas B-cell lym-
phoma family and post-translational modifications of
suppressor of cytokine signalling proteins (Vainchenker et al,
2011). Proinflammatory cytokines that have been implicated
in MF are known to signal through JAK1 and JAK2 (Vain-
chenker et al, 2008) and symptoms of MF have been linked
to elevated levels of these cytokines (Verstovsek, 2009; Tefferi
et al, 2011). An association between elevated cytokines and
decreased survival has also been reported (Tefferi et al,
2011).
A broad spectrum of disease characteristics exists within
the MF patient population (Cervantes et al, 1997, 2009).
Patients often experience constitutional symptoms (e.g. fever,
night sweats, weight loss) and splenomegaly, which may
cause disability and have a profound impact on quality of life
(Mesa et al, 2007); however, other MF-related symptoms,
such as fatigue (84%), itching (50%) and bone pain (47%),
are also common and burdensome to patients (Mesa et al,
2007).
Patients with MF have shortened survival, and those with
advanced MF have a poor prognosis (Barbui et al, 2011).
The major prognostic scoring systems used to categorize risk
in patients with MF are the International Prognostic Scoring
System (IPSS) (Cervantes et al, 2009), the Dynamic Interna-
tional Prognostic Scoring System (DIPSS) (Passamonti et al,
2010) and DIPSS Plus (Gangat et al, 2011). Risk factors for
shorter survival in both the IPSS and DIPSS are age
>65 years, presence of constitutional symptoms, haemoglobin
<100 g/l, white blood cell count >25 9 109/l and peripheral
blood blasts  1% (Cervantes et al, 2009; Passamonti et al,
2010). The DIPSS Plus adds platelet count <100 9 109/l, red
blood cell transfusion status and unfavourable karyotype to
these prognostic criteria (Gangat et al, 2011). Depending on
risk factors/category, median survival can range from
112 years (low risk) to 22 years (high risk) according to the
IPSS (Cervantes et al, 2009), with wider ranges for survival
across risk groups for the DIPSS (Passamonti et al, 2010)
and DIPSS Plus (Gangat et al, 2011).
Although factors that influence disease burden and survival
have been published, there is little information regarding how
these factors influence treatment efficacy. In the randomized,
double-blind, placebo-controlled COMFORT (COntrolled
MyeloFibrosis Study With ORal JAK Inhibitor Treatment)-I
trial, ruxolitinib, a JAK1/JAK2 inhibitor, significantly reduced
spleen volume and improved MF-related symptoms, and was
associated with a survival advantage compared with placebo
(Verstovsek et al, 2012). The current analysis evaluated the
consistency of ruxolitinib efficacy across MF patient sub-
groups in the COMFORT-I trial.
Methods
Patients and study design
The COMFORT-I study design was previously published
(Verstovsek et al, 2012). The primary inclusion criteria were
age 18 years or older; diagnosis of PMF, PPV-MF or PET-
MF based on 2008 World Health Organization criteria (Tef-
feri & Vardiman, 2008); life expectancy 6 months or longer;
IPSS score (Cervantes et al, 2009) of 2 (intermediate-2 risk)
or  3 (high risk); Eastern Cooperative Oncology Group
(ECOG) performance status  3 (Oken et al, 1982); periph-
eral blood blasts <10%; absolute peripheral blood CD34 +
cell count >20 9 106/l; platelet count  100 9 109/l; and
palpable splenomegaly ( 5 cm below left costal margin). An
institutional review board at each site approved the protocol.
The study was conducted in accordance with Good Clinical
Practice guidelines per the International Conference on Har-
monization. All patients provided written informed consent.
The study is registered at ClinicalTrials.gov (NCT00952289).
Patients were randomized 1:1 to placebo or ruxolitinib at
an oral dose of 15 mg or 20 mg twice daily depending on
baseline platelet count (100–200 9 109/l or >200 9 109/l
respectively). The dose was optimized for efficacy and safety
during treatment. The primary analysis data cut-off occurred
when half of the patients remaining in the study completed
the week 36 visit and all had either completed the week 24
evaluation or discontinued treatment. All patients receiving
placebo were eligible for crossover to ruxolitinib after the
primary analysis data cut-off. Early unblinding and crossover
from placebo to ruxolitinib was permitted prior to week 24
for a  25% increase in spleen volume from baseline
accompanied by worsening early satiety with weight loss or
worsening splenic pain (demonstrated by increased require-
ment for narcotics). The primary endpoint was the propor-
tion of patients achieving  35% reduction from baseline in
spleen volume at week 24. Secondary endpoints included the
duration of maintenance of spleen volume reduction, the
proportion of patients with  50% reduction in Total Symp-
tom Score (TSS) from baseline to week 24 using the modi-
fied Myelofibrosis Symptom Assessment Form v2.0 electronic
diary, the change in TSS from baseline to week 24, and over-
all survival. The MF symptoms assessed were night sweats,
itching (pruritus), abdominal discomfort, pain under the ribs
on the left side, feeling of fullness (early satiety), muscle/bone
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pain and inactivity on a scale of 0 (absent) to 10 (worst
imaginable). The TSS was the average of the daily sum of
individual symptom scores over a 7-day period for baseline
and over a 28-day period for week 24, except for the inactiv-
ity score, which was analysed separately (Verstovsek et al,
2012).
Statistical analyses
Patient subgroups were based on the following: MF subtype
(PMF, PPV-MF, PET-MF), age ( 65, >65 years), IPSS risk
group, baseline ECOG performance status (0, 1,  2), pres-
ence/absence of JAK2 V617F mutation, baseline haemoglobin
( 100, <100 g/l), baseline platelet count (100–200 9 109/l,
>200 9 109/l) and baseline palpable spleen size ( 10,
>10 cm). Additional subgroups included baseline quartile of
palpable spleen size and baseline quartile of TSS (Q1 = low-
est and Q4 = highest). Mean percentage change from base-
line in spleen volume and TSS were calculated for each
subgroup. Possible subgroup by treatment interaction was
evaluated by using analysis of covariance method with base-
line, sex, age group, myelofibrosis type, previous hydroxycar-
bamide use, JAK2 V617F mutation status, subgroup,
treatment and subgroup by treatment interaction as the
model effects.
Overall survival was estimated by Kaplan–Meier method
according to original randomization group, regardless of
crossover to ruxolitinib, for the intention-to-treat population
(N = 309). The analysis was carried out for each subgroup
separately. The COMFORT-I study was designed to follow
patients even after they discontinued study treatment (Vers-
tovsek et al, 2012). The survival analysis in this evaluation
included 4 additional months of follow-up beyond the pri-
mary analysis data cut-off, corresponding to the time of a
pre-specified safety update. Hazard ratios (HRs) for ruxoliti-
nib versus placebo with 95% confidence intervals (CIs) were
estimated using the Cox proportional hazard regression
method.
The trial was not designed or powered to detect differ-
ences in efficacy between treatment arms within a subgroup.
Subgroup analyses were intended only to assess the
uniformity of treatment effect found in the overall patient
population (Second International Study of Infarct Survival
(ISIS-2) Collaborative Group, 1988; Cuzick, 2005).
Results
A total of 309 patients were randomized, 155 to ruxolitinib
(median age, 66 years) and 154 to placebo (median age,
70 years). As previously reported, the study arms were bal-
anced in terms of demographics and baseline disease charac-
teristics (Verstovsek et al, 2012). Among the 154 patients in
the placebo arm, 111 crossed over to ruxolitinib, 40 before
study unblinding and 71 after study unblinding. The median
time to crossover was 411 weeks.
Changes in spleen volume and TSS across subgroups
Ruxolitinib demonstrated a benefit over placebo with respect
to both spleen volume (Fig 1) and TSS (Fig 2) across all
subgroups evaluated. The mean percentage change from
baseline to week 24 in spleen volume (Fig 1) and TSS (Fig 2)
consistently improved (i.e. decreased) in patients receiving
ruxolitinib treatment and worsened in patients receiving
placebo across all subgroups evaluated. Mean percentage
changes from baseline to week 24 in ruxolitinib-treated
patients in each subgroup were similar to mean percentage
changes in spleen volume (316%) and TSS (461%) in
ruxolitinib-treated patients in the overall study population
(Verstovsek et al, 2012).
Although there was no subgroup that did not benefit from
ruxolitinib therapy with respect to spleen volume reductions
and TSS improvements, interaction tests were performed to
further assess if baseline characteristics affect treatment
outcome. For the mean percentage change from baseline to
week 24 in spleen volume, subgroup by treatment interaction
P-values for age, JAK2 V617F mutation status and baseline
platelet count were all <010. The results for JAK2 V617F
mutation status (P-value = 007) and baseline platelet count
(P-value = 006) were driven predominantly by differences in
the magnitude of spleen volume reductions between ruxoliti-
nib-treated patients, with similar levels of spleen growth rela-
tive to baseline noted in placebo-treated patients. In contrast,
the result for age (P-value = 002) was driven by differences
in the magnitude of spleen volume increases between patients
receiving placebo, with similar reductions in spleen volume
relative to baseline noted in ruxolitinib-treated patients
regardless of age. For the mean percentage change from base-
line to week 24 in TSS, the subgroup by treatment interac-
tion for baseline haemoglobin (P-value = 007) was primarily
driven by differences in the magnitude of TSS worsening
between patients receiving placebo. Patients receiving placebo
with baseline haemoglobin <100 g/l had greater worsening of
their TSS than those with haemoglobin  100 g/l, while
similar degrees of improvement in TSS relative to baseline
were observed in ruxolitinib-treated patients regardless of
baseline haemoglobin. Regardless of the quantitative differ-
ences observed in these subgroups, ruxolitinib-treated
patients consistently experienced reductions in spleen volume
and improvements in TSS with therapy while patients
receiving placebo experienced worsening on these measures.
For the remaining subgroup by treatment interaction tests,
all P-values were  010.
Patients treated with ruxolitinib experienced reductions in
spleen volume and improvements in TSS regardless of spleen
volume or symptom severity at baseline. Analysis by baseline
spleen volume quartile showed mean reductions in spleen
volume that ranged from 29.2% to 33.9% (Fig 3A) and
mean changes in TSS that ranged from 36.2% to 56.7%
(Fig 3B). Analysis by baseline TSS quartile showed mean
reductions in spleen volume ranging from –283% to –348%
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(Fig 3C). Mean changes in TSS ranged from –372%
to –514% (Fig 3D). In contrast, mean changes in spleen vol-
ume and TSS in patients receiving placebo (all quartiles com-
bined) were +82% and +418% respectively.
Survival analysis
Overall, there were 13 deaths in the ruxolitinib group and
24 in the placebo group during the follow-up period (median
follow-up, 51 weeks), representing a HR of 050 (95% CI: 025
–098) (P = 004) (Verstovsek et al, 2012). In the subgroup
analyses of overall survival (Fig 4 and 5), HRs consistently
favoured ruxolitinib over placebo (range, 022–067), with the
exception of the PET-MF subgroup (112); this probably was
the result of the low frequency of events (three in total) in this
small subgroup. Among patients in the placebo group, those
with low haemoglobin had a particularly poor prognosis
(Fig 5F), whereas patients with low haemoglobin who received
ruxolitinib appeared to achieve benefits (HR = 059) consis-
tent with those observed in other ruxolitinib-treated patients.
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Discussion
Heterogeneity in patient disease characteristics has been
observed in the MF population (Tefferi, 2000; Mesa et al,
2007; Cervantes et al, 2009). Thus, a ‘typical’ MF patient is
difficult to characterize. In this analysis, ruxolitinib was
shown to be effective in reducing spleen volume and improv-
ing MF-related symptoms regardless of MF subtype, age
group, IPSS risk group, baseline ECOG performance status,
presence/absence of JAK2 V617F mutation, baseline
haemoglobin, baseline platelet count, baseline palpable spleen
size, baseline spleen volume quartile or baseline TSS quartile.
In contrast, spleen volume and symptoms worsened across
all evaluated subgroups of patients receiving placebo. These
data indicate that, among the population studied in COM-
FORT-I, there was no subgroup that did not benefit from
ruxolitinib therapy and there was no subgroup that did not
worsen with placebo.
The COMFORT-I study was designed to follow patients for
survival, even after they discontinued study treatment. The
current evaluation of survival is an intention-to-treat analysis,
so patients were grouped according to the original randomiza-
tion, regardless of crossover. At the time of the updated
survival analyses (4 additional months of follow-up beyond
the primary analysis data cut-off; median follow-up duration
of 51 weeks), all but two patients had crossed over from the
placebo arm to ruxolitinib. Although subgroup comparisons
were not powered to show statistically significant differences,
the observed prolongation of survival in favour of ruxolitinib
relative to placebo was seen across subgroups and was gener-
ally consistent with that observed in the total COMFORT-I
study population (Verstovsek et al, 2012).
Baseline patient characteristics, such as age >65 years, pres-
ence of constitutional symptoms and haemoglobin <100 g/l,
are prognostic for shorter survival (Cervantes et al, 2009;
Passamonti et al, 2010). In this study, ruxolitinib was associated
with a survival advantage over placebo in intermediate-2 and
high-risk patients based on IPSS, as well as in sub-
groups defined by factors included in IPSS risk stratification
(e.g. age, haemoglobin). Notably, patients in the placebo arm
who had low haemoglobin (<100 g/l) had a particularly poor
prognosis, and in patients with low haemoglobin, ruxolitinib
treatment was associated with evidence of improved survival.
The mechanism underlying the prolonged survival relative to
placebo associated with ruxolitinib treatment in COMFORT-
I is not clear and is probably multifactorial. However, we
believe that reductions in spleen volume and resolution of
MF symptoms may have contributed to the observed prolon-
gation of survival in this study. Among 517 deaths in PMF
patients described by Cervantes et al (2009), 86 (17%)
and 50 (10%) were because of progression to acute myeloid
leukaemia and progression of PMF respectively. Thrombosis
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and cardiovascular complications, infection, bleeding (not
related to acute transformation) and portal hypertension
accounted for 92 deaths (18%). The prolonged survival asso-
ciated with ruxolitinib relative to placebo in this study may
in part be the result of a modulatory or secondary effect
related to those causes of death not attributable to disease
progression. For example, resolution of splenomegaly may
reduce the risk of portal hypertension in patients with MF.
Although the IPSS (Cervantes et al, 2009) and DIPSS
(Passamonti et al, 2010) are tools used for risk stratification
of MF patients (and also entry in the COMFORT-I study
and ongoing clinical trials), a great degree of patient hetero-
geneity may exist within IPSS/DIPSS risk categories. For
example, symptom assessment within these instruments is
limited to the presence/absence of constitutional symptoms.
Both exclude potentially significant symptoms that result
from splenomegaly, as well as bothersome symptoms such as
pruritus, abdominal pain/discomfort, early satiety and bone
pain. These symptoms, although not ‘constitutional,’ may be
associated with advanced disease and cause substantial
disability and/or adversely affect quality of life. Thus, it is
important to assess the effects of therapy on aspects of the
disease that are not captured by the current prognostic scor-
ing systems. The COMFORT-I study assessed the effects of
ruxolitinib on splenomegaly and TSS (a composite score rep-
resenting six MF-related symptoms, including constitutional
and other symptoms). In this present analysis, ruxolitinib
improved both spleen volume and TSS compared with pla-
cebo, regardless of the degree of splenomegaly or symptom
burden at baseline.
As with all subgroup analyses, there are limitations to the
present analyses. The purpose of subgroup analyses is to
explore the overall heterogeneity of treatment effect across
subgroups relative to the overall treatment effect observed
in the trial. Small sample sizes within individual subgroups
and a large number of different comparisons preclude firm
conclusions regarding the absence or presence of benefit
limited to any particular subgroup (Second International
Study of Infarct Survival (ISIS-2) Collaborative Group,
1988; Cuzick, 2005). However, the results support the treat-
ment effects of ruxolitinib across subgroups that are similar
to those observed in the overall COMFORT-I population.
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HR = 0·55 (0·26–1·18)
Ruxolitinib (n = 64) Placebo (n = 54)
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(F)Haemoglobin ≥100 g/l(E)
HR = 0·37 (0·09–1·42)
Ruxolitinib (n = 71) Placebo (n = 76)
Haemoglobin <100 g/l*
HR = 0·59 (0·27–1·29)
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(H)Spleen length ≤10 cm(G)
HR = 0·67 (0·11–4·03)
Ruxolitinib (n = 123) Placebo (n = 126)
Spleen length >10 cm
HR = 0·49 (0·23–1·01)
Fig 5. Overall survival by (A, B) JAK2 V617F mutation status, (C, D) baseline IPSS risk category, (E, F) baseline haemoglobin level and (G, H)
baseline palpable spleen length. *Patients who received  1 unit of RBC transfusions within 12 weeks before baseline were assigned to the
haemoglobin <100-g/l subgroup. HR, hazard ratio; IPSS, International Prognostic Scoring System; RBC, red blood cell.
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In conclusion, results from these subgroup analyses con-
firm that there was little heterogeneity of treatment benefit
in COMFORT-I, and that ruxolitinib is an effective therapy
for the spectrum of MF patients enrolled in this study.
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